We then compared the activity of Bn-dU SOMAmer SL1026 with tocilizumab in the U266B1 human myeloma cell proliferation assay as described under “Experimental Procedures.” SL1026 achieved complete inhibition of IL-6 at 1 μg/ml (83 nm), whereas tocilizumab achieved 60% inhibition at a roughly equivalent molar concentration (67 nm) (Fig. 8A). This evidence concerns the gene IL6 and plasma cell myeloma.